Weekly docetaxel monotherapy for advanced gastric or esophagogastric junction cancer Results of a phase II study in elderly patients or patients with impaired performance status.

BACKGROUND: Three-weekly docetaxel is active in patients with advanced esophagogastric cancer but myelosuppression may make this schedule unsuitable for some patient groups such as elderly, pretreated, or poor performance status patients. PATIENTS AND METHODS: Eligible patients were chemonaive with Karnofsky index /=70 years) included, 87% had Karnofsky index /=100 days (disease stabilization rate: 36%). Overall response rate was 9%; median overall survival was 7.0 months. CONCLUSIONS: Weekly docetaxel was well tolerated and achieved disease stabilization in one-third of difficult-to-treat patients.     «

BACKGROUND: Three-weekly docetaxel is active in patients with advanced esophagogastric cancer but myelosuppression may make this schedule unsuitable for some patient groups such as elderly, pretreated, or poor performance status patients. PATIENTS AND METHODS: Eligible patients were chemonaive with Karnofsky index /=70 years) included, 87% had Karnofsky index /=100 days (disease stabilization rate: 36%). Overall response rate was 9%; median overall survival was 7.0 months. CONCLUSIONS: Weekly d...     »